Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,187 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07741903 | Development of a Risk Prediction Model for Immune-Targeted Therapy-Related Diarrhea in Patients With Hepatocellular Carcinoma Based on TCM Constitutional Types: A Prospective Cohort Study | not yet recruiting | — | 500 | Affiliated Hospital of Chengde Medical UniversityOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | not yet recruiting | Phase 1 | 120 | Iksuda Therapeutics Ltd.INDUSTRY | 1 |
| Jul 31, 2026 |
| clinicaltrials |
| NCT07732504 | AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation(HCC-AI-RECLAIM) | not yet recruiting | N/A | 2,000 | Tongji HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | not yet recruiting | — | 2,000 | University of OklahomaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734857 | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07729917 | Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study | not yet recruiting | Phase 2 | 240 | Zhejiang UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study | not yet recruiting | — | 400 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729033 | A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy. | not yet recruiting | Phase 2 | 28 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07729618 | AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma(HCC-AI-SELECT) | not yet recruiting | N/A | 1,800 | Tongji HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07723534 | Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers | not yet recruiting | Phase 2 | 32 | Midhun MallaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07690683 | Patients With Hepatocellular Carcinoma (HCC)(FORCE) | not yet recruiting | N/A | 52 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716345 | Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer | not yet recruiting | — | 100 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | not yet recruiting | Phase 1 / Phase 2 | 90 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07707661 | Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor(SRUS) | not yet recruiting | — | 350 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | not yet recruiting | Early Phase 1 | 6 | Royan InstituteOTHER_GOV | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07704203 | Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy | not yet recruiting | — | 150 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704216 | Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer | not yet recruiting | — | 150 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07691515 | Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma(RAINBOW) | not yet recruiting | Phase 3 | 140 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07701122 | Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07685548 | AI-Driven Tumor Response Evaluation for Solid Tumors | not yet recruiting | — | 6,120 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07675187 | HCC Risk and Monitoring in Patients With Type 2 Diabetes(GAAD-DM) | not yet recruiting | N/A | 2,400 | National Taiwan University HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687914 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 50 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07684040 | A Study of Combination Therapy in Patients With Resectable Liver Cancer(Archer) | not yet recruiting | Phase 2 | 68 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07685535 | HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 29 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07681817 | Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer | not yet recruiting | N/A | 200 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | not yet recruiting | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07110233 | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma | not yet recruiting | N/A | 64 | University of California, San FranciscoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07667608 | Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings | not yet recruiting | — | 120 | Assiut UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07668024 | Study of Occupational Risk Factors for Biliary and Pancreatic Cancers(PANTOXBIL) | not yet recruiting | — | 210 | Centre Hospitalier Intercommunal CreteilOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 36 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07658313 | Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery(P2R-OncoVis) | not yet recruiting | N/A | 30 | Ludwig Boltzmann Institute for Digital Health and PreventionOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07558304 | Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial)(SMART-B) | not yet recruiting | N/A | 84 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649980 | Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II | not yet recruiting | Phase 2 | 30 | HuiKai LiOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07644208 | PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07638501 | Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer | not yet recruiting | Phase 2 | 123 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639801 | 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors | not yet recruiting | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07629193 | Liver Transplant for Hepatocellular Carcinoma(TH-CHC) | not yet recruiting | — | 562 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07630610 | Feasibility and Safety of Augmented Reality (AR) in Liver Tumor Surgery | not yet recruiting | N/A | 6 | Navari Surgical ABINDUSTRY | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07620080 | EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis(EYE/SPY) | not yet recruiting | N/A | 120 | David KARSENTIOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07618546 | A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors | not yet recruiting | N/A | 208 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07495579 | Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)(REVIVE) | not yet recruiting | Phase 2 | 146 | Asan Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07581730 | A Subharmonic-Aided Pressure Estimate Technology for Prediction of Response to Systemic Therapy in Gastric Cancer Liver Metastases | not yet recruiting | — | 107 | The First Hospital of Jilin UniversityOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07587034 | HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 315 | Shanghai Zhongshan HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 3, 2026source: clinicaltrials